1. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment.
- Author
-
Wang H, Wang X, Zhou XY, Chen DJ, Li GC, Iliakis G, and Wang Y
- Subjects
- Animals, Ataxia Telangiectasia Mutated Proteins, Checkpoint Kinase 1, DNA biosynthesis, DNA-Binding Proteins genetics, Down-Regulation, Fibroblasts cytology, Fibroblasts drug effects, Fibroblasts enzymology, Humans, Ku Autoantigen, Mice, Mice, Knockout, Nuclear Proteins genetics, Oligonucleotides, Antisense genetics, Oligonucleotides, Antisense pharmacology, Protein Kinase Inhibitors, Protein Kinases genetics, S Phase physiology, Antigens, Nuclear, Camptothecin pharmacology, Cell Cycle Proteins metabolism, DNA Helicases, DNA-Binding Proteins physiology, Nuclear Proteins physiology, Protein Kinases metabolism, Protein Serine-Threonine Kinases, S Phase drug effects
- Abstract
Camptothecin (CPT) that targets DNA topoisomerase I is one of the most promising broad-spectrum anticancer drugs in development today. The cytotoxicity of CPT is S phase (S)-specific because the collision of advancing replication forks with CPT-topoisomerase I-DNA complexes results in DNA damage. After DNA damage, proliferating cells could actively slow down the DNA replication through an S checkpoint to provide time for repair. We report now that there is an activated S checkpoint response in CPT-treated mammalian cells. This response is regulated by Ataxia and Rad3-related (ATR)/CHK1 pathway. Compared with their wild-type counterparts, CPT-treated Ku80-/- cells showed stronger inhibition of DNA replication. This stronger inhibition had no relationship with DNA-dependent protein kinase (DNA-PK) activity but correlated with the higher activities of ATR and the higher activities of CHK1 in such cells. Not only caffeine, the nonspecific inhibitor of ATR, or UCN-01, the nonspecific inhibitor of CHK1, but also the specific CHK1 antisense oligonucleotide abolished the stronger inhibition of DNA replication in CPT-treated Ku80-/- cells. These results in aggregate indicated that the stronger S checkpoint in CPT-treated Ku80-/- cells is regulated through the highly activated ATR/CHK1 pathway.
- Published
- 2002